» Articles » PMID: 28224203

Nucleic Acid Sensing Pattern Recognition Receptors in the Development of Colorectal Cancer and Colitis

Overview
Publisher Springer
Specialty Biology
Date 2017 Feb 23
PMID 28224203
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Colorectal cancer (CRC) is a leading cause of cancer-related deaths that is often associated with inflammation initiated by activation of pattern recognition receptors (PRRs). Nucleic acid sensing PRRs are one of the major subsets of PRRs that sense nucleic acid (DNA and RNA), mainly including some members of Toll-like receptors (TLR3, 7, 8, 9), AIM2-like receptors (AIM2, IFI16), STING, cGAS, RNA polymerase III, and DExD/H box nucleic acid helicases (such as RIG-I like receptors (RIG-I, MDA5, LPG2), DDX1, 3, 5, 7, 17, 21, 41, 60, and DHX9, 36). Activation of these receptors eventually leads to the release of cytokines and activation of immune cells, which are well known to play crucial roles in host defense against intracellular bacterial and virus infection. However, the functions of these nucleic acid sensing PRRs in the other diseases such as CRC and colitis remain largely unknown. Recent studies indicated that nucleic acid sensing PRRs contribute to CRC and/or colitis development, and therapeutic modulation of nucleic acid sensing PRRs may reduce the risk of CRC development. However, until now, a comprehensive review on the role of nucleic acid sensing PRRs in CRC and colitis is still lacking. This review provided an overview of the roles as well as the mechanisms of these nucleic acid sensing PRRs (AIM2, STING, cGAS, RIG-I and its downstream molecules, DDX3, 5, 6,17, and DHX9, 36) in CRC and colitis, which may aid the diagnosis, therapy, and prognostic prediction of CRC and colitis.

Citing Articles

m5C methylation modification may be an accomplice in colorectal cancer escaping from anti-tumor effects of innate immunity-type I/III interferon.

Sun Y, Liu Y, Jiang L, Zhong C Front Immunol. 2025; 15:1512353.

PMID: 39867908 PMC: 11757137. DOI: 10.3389/fimmu.2024.1512353.


AIM2 enhances Candida albicans infection through promoting macrophage apoptosis via AKT signaling.

Jiang Q, Chen Y, Zheng S, Sui L, Yu D, Qing F Cell Mol Life Sci. 2024; 81(1):280.

PMID: 38918243 PMC: 11335202. DOI: 10.1007/s00018-024-05326-9.


Dysfunction of STING Autophagy Degradation in Senescent Nucleus Pulposus Cells Accelerates Intervertebral Disc Degeneration.

Chen Z, Chen C, Yang X, Zhou Y, Cao X, Han C Int J Biol Sci. 2024; 20(7):2370-2387.

PMID: 38725841 PMC: 11077376. DOI: 10.7150/ijbs.88534.


The tRNA half: A strong endogenous Toll-like receptor 7 ligand with a 5'-terminal universal sequence signature.

Pawar K, Kawamura T, Kirino Y Proc Natl Acad Sci U S A. 2024; 121(19):e2319569121.

PMID: 38683985 PMC: 11087793. DOI: 10.1073/pnas.2319569121.


GPR162 activates STING dependent DNA damage pathway as a novel tumor suppressor and radiation sensitizer.

Long Y, Guo J, Chen J, Sun J, Wang H, Peng X Signal Transduct Target Ther. 2023; 8(1):48.

PMID: 36725837 PMC: 9892510. DOI: 10.1038/s41392-022-01224-3.


References
1.
Bode C, Fox M, Tewary P, Steinhagen A, Ellerkmann R, Klinman D . Human plasmacytoid dentritic cells elicit a Type I Interferon response by sensing DNA via the cGAS-STING signaling pathway. Eur J Immunol. 2016; 46(7):1615-21. PMC: 6389263. DOI: 10.1002/eji.201546113. View

2.
Cardoso S, Ryan G, Walne A, Ellison A, Lowe R, Tummala H . Germline heterozygous DDX41 variants in a subset of familial myelodysplasia and acute myeloid leukemia. Leukemia. 2016; 30(10):2083-2086. PMC: 5008455. DOI: 10.1038/leu.2016.124. View

3.
Fu J, Kanne D, Leong M, Glickman L, McWhirter S, Lemmens E . STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade. Sci Transl Med. 2015; 7(283):283ra52. PMC: 4504692. DOI: 10.1126/scitranslmed.aaa4306. View

4.
Furi I, Sipos F, Germann T, Kalmar A, Tulassay Z, Molnar B . Epithelial toll-like receptor 9 signaling in colorectal inflammation and cancer: clinico-pathogenic aspects. World J Gastroenterol. 2013; 19(26):4119-26. PMC: 3710413. DOI: 10.3748/wjg.v19.i26.4119. View

5.
Corrales L, Glickman L, McWhirter S, Kanne D, Sivick K, Katibah G . Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. Cell Rep. 2015; 11(7):1018-30. PMC: 4440852. DOI: 10.1016/j.celrep.2015.04.031. View